L3VLUP
ProSign in

TXG · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TXGJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TXG
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTXGJNJ
Q3 202017 holders, $1.8bn30 holders, $26.2bn
Q4 202014 holders, $1.9bn32 holders, $26.6bn
Q1 202110 holders, $3.0bn31 holders, $25.3bn
Q2 20218 holders, $3.7bn37 holders, $25.6bn
Q3 20217 holders, $2.6bn40 holders, $24.1bn
Q4 20217 holders, $2.9bn33 holders, $25.2bn
Q1 20225 holders, $849m35 holders, $28.2bn
Q2 20225 holders, $642m33 holders, $26.9bn
Q3 20225 holders, $425m36 holders, $25.4bn
Q4 20226 holders, $546m35 holders, $27.6bn
Q1 202310 holders, $995m42 holders, $24.5bn
Q2 202311 holders, $1.4bn38 holders, $25.0bn
Q3 202312 holders, $1.3bn37 holders, $18.9bn
Q4 20239 holders, $1.7bn31 holders, $19.0bn
Q1 202410 holders, $1.2bn32 holders, $19.7bn
Q2 20246 holders, $289m35 holders, $20.4bn
Q3 20247 holders, $337m28 holders, $22.3bn
Q4 20246 holders, $247m37 holders, $20.4bn
Q1 20257 holders, $165m32 holders, $20.5bn
Q2 20258 holders, $231m31 holders, $18.4bn
Q3 20256 holders, $187m32 holders, $23.7bn
Q4 20255 holders, $272m29 holders, $27.8bn
Q1 20262 holders, $259m34 holders, $35.6bn
Q2 20265 holders, $1.2bn33 holders, $39.1bn
TXG

10X Genomics Inc

Holders
6
Reported value
$289m
Buyers
4
Sellers
1

Breadth +3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TXG (5)

ARK Investment Management LLC, Baillie Gifford & Co, Capital World Investors, ExodusPoint Capital Management LP, PDT Partners LLC

Only JNJ (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, and 9 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →